within Pharmacolibrary.Drugs.ATC.L;

model L01FA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00024333333333333333,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0058,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0072,
    k12             = 24.9,
    k21             = 24.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ofatumumab is a fully human monoclonal antibody that targets the CD20 molecule on B lymphocytes, leading to cell lysis predominantly through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. It is approved for the treatment of chronic lymphocytic leukemia (CLL) and is also approved (under a different formulation and dosing) for relapsing forms of multiple sclerosis (MS).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics were evaluated in adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after intravenous infusion. Population pharmacokinetic analysis was performed for multiple doses.</p><h4>References</h4><ol><li><p>Struemper, H, et al., &amp; Jewell, RC (2014). Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. <i>Journal of clinical pharmacology</i> 54(7) 818–827. DOI:<a href=&quot;https://doi.org/10.1002/jcph.268&quot;>10.1002/jcph.268</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24443277/&quot;>https://pubmed.ncbi.nlm.nih.gov/24443277</a></p></li><li><p>Bellot, M, et al., &amp; Hellwig, K (2022). Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. <i>Reproductive toxicology (Elmsford, N.Y.)</i> 108 28–34. DOI:<a href=&quot;https://doi.org/10.1016/j.reprotox.2021.12.006&quot;>10.1016/j.reprotox.2021.12.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34942355/&quot;>https://pubmed.ncbi.nlm.nih.gov/34942355</a></p></li><li><p>Nightingale, G (2011). Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. <i>The Annals of pharmacotherapy</i> 45(10) 1248–1255. DOI:<a href=&quot;https://doi.org/10.1345/aph.1P780&quot;>10.1345/aph.1P780</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21896924/&quot;>https://pubmed.ncbi.nlm.nih.gov/21896924</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FA02;
